^
    Back
    Association details:
    Biomarker:BRAF V600K + CDKN2A deletion + RB1 expression
    Cancer:Melanoma
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase I-II open label multicenter study of palbociclib + vemurafenib in BRAFV600MUT metastatic melanoma patients: uncovering CHEK2 as a major response mechanism

    Published date:
    05/04/2021
    Excerpt:
    BRAFV600E/KMUT metastatic melanoma patients harboring CDKN2A loss and RB1 expression were included...Treatment comprised palbociclib once daily for 14 days followed by a 7-day break + continuous dosing of vemurafenib....The median PFS was 2.8 months, and 5 (27.8%) patients showed a clinical response.
    DOI:
    10.1158/1078-0432.CCR-20-4050